Opexa Therapeutics, Inc., a drug delivery company based in The Woodlands, Texas, has been making significant progress in researching and developing Tcelna®, a breakthrough T-cell immunotherapy for multiple sclerosis (MS). The company recently announced they have reached their enrollment mark for conducting a Phase IIb clinical trial to test Tcelna as a viable…
SPMS
Recommended Posts
- AAN 2026: Ocrevus preserves walking, hand function in early RRMS
- My husband’s MS diagnosis changed everything — and nothing
- Enrollment complete in Phase 3 trial of at-home Briumvi injection for MS
- ‘Objective improvements’ in sleep seen with use of mindfulness in MS
- The ins, outs, ups, and downs of choosing an MS-accessible minivan